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The emergence of antibiotic resistance places a
sense of urgency on the development of alternative
antibacterial strategies, of which targeting virulence
factors has been regarded as a ‘‘second generation’’
antibiotic approach. In the case of Pseudomonas
aeruginosa infections, a proteolytic virulence factor,
LasB, is one such target. Unfortunately, we and
others have not been successful in translating
in vitro potency of LasB inhibitors to in vivo efficacy
in an animal model. To overcome this obstacle, we
now integrate in silico and in vitro identification of
the mercaptoacetamide motif as an effective class
of LasB inhibitors with full in vivo characterization
ofmercaptoacetamide prodrugs usingCaenorhabdi-
tis elegans. We show that one of our mercaptoaceta-
mide prodrugs has a good selectivity profile and high
in vivo efficacy, and confirm that LasB is a promising
target for the treatment of bacterial infections. In
addition, our work highlights that the C. elegans
infection model is a user-friendly and cost-effective
translational tool for the development of anti-viru-
lence compounds.
INTRODUCTION
Pseudomonas aeruginosa is a nosocomial, opportunistic, Gram-
negative bacteria causing various diseases including acute in-
fections in immunocompromised patients and chronic lung infec-
tions in individuals with cystic fibrosis (Mesaros et al., 2007;
Cohen and Prince, 2012). At the clinical level, P. aeruginosa is
able to rapidly develop antibiotic resistance and form biofilms,
thus it is extremely difficult to treat infected patients (Breidenstein
et al., 2011).Moreover,P. aeruginosa infections are usually asso-
ciated with a high morbidity and mortality rate ranging from 20%
to 75%, despite improvements in hospital care. This undeniable
medical challenge brings a sense of urgency to the development
of alternative antibacterial strategies to currently available medi-
cations (El Solh and Alhajhusain, 2009; El-Solh et al., 2012).Chemistry & Biology 22,The targeting of bacterial virulence factors as an effective
means to control bacterial infections holds particular promise
(Barczak and Hung, 2009; Clatworthy et al., 2007). Pathogenic
bacteria produce virulence factors such as adhesion molecules,
secretion systems, and other toxic factors including proteases
to enhance their ability to cause disease and damage the host’s
tissues (Clatworthy et al., 2007). Indeed, P. aeruginosa pathogen-
esis presents itself through coordination of the expression of a
plethora of virulence factors (Mesaros et al., 2007). Elastase B,
also known as pseudolysin (LasB), is a zinc metalloprotease
encoded by the lasB gene (Morihara et al., 1965). LasB has
beenshown tobehighly toxic to thehost through itsenzymaticac-
tivity to degrade numerous components of innate and adaptive
immune systems (Wretlind and Pavlovskis, 1983; Schultz and
Miller, 1974; Mariencheck et al., 2003; Alcorn and Wright, 2004;
Parmely et al., 1990). LasB can cause host tissue damage via
hydrolysis of various components of the extracellular matrix and
by breaching endothelial and epithelial barriers by attacking
intercellular tight junctions (Azghani, 1996; de Bentzmann et al.,
2000). Furthermore, proteomic analyses of laboratory and clinical
P. aeruginosa strains have revealed that LasB production is
increased in isolates fromcritically ill patients and ventilator-asso-
ciated pneumoniae, and LasB activity is directly connected to the
pro-inflammatoryeffectsofP.aeruginosa infection (LeBerreet al.,
2008; Bergamini et al., 2012). There are also reports of LasBbeing
linked to P. aeruginosa biofilm formation and swarming (Tielen
et al., 2010; Cathcart et al., 2011; Reimmann et al., 2002), sug-
gesting a role in bacterial elution from the host’s immune system.
Current animal models of P. aeruginosa infection include acute
and chronic infections in mice and rats (Pavlovskis andWretlind,
1979). Using these mammalian models, mitigation of bacterial
virulence through disruption of LasB function has been demon-
strated, suggesting that LasB is a promising therapeutic target
(Kessler et al., 1983; Burns et al., 1990). Intriguing as the idea
of virulence targeting is, a number of sobering fundamental
challenges need to be addressed en route to the development
of a viable LasB inhibitor. Foremost is that no LasB inhibitor
has had its in vitro potency translate to in vivo efficacy in an
animal model (Lewis, 2013). This discourse has led us to pursue
a more practical non-mammalian animal model, C. elegans, for
LasB inhibition optimization. Importantly, the strategies we
disclose here for LasB in vivo targeting should be readily appli-
cable to other bacterial virulence factors.483–491, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 483
Figure 1. Hits Identified from In Silico and In Vitro Studies
Compounds identified from molecular docking studies and shown to inhibit
LasB in vitro. Compounds 1, 2, and 3 possessed IC50 values of 156 ± 8, 27.4 ±
2.5, and 15.7 ± 3.1 mM, respectively.
Figure 2. LasB Inhibitor Docked in the Active Site of Metalloprotei-
nase
Compound 13 is shown docked using the Autocorrelator-derived model from
the 3DBK structure. The docked orientation shows a close proximity between
the thiol and zinc, a hydrogen bond between the amide of 13 and Asn112,
and the phenyl ring shielding a collection of hydrophobic residues consisting
of Phe129, Leu132, Val137, Ile190, and Leu197. Distance displayed in ang-
stroms.RESULTS
Virtual and In Vitro Screening against LasB
To initiate our screening efforts, virtual screening of all commer-
cially available molecules from eMolecules containing a thiol
appendage was performed. Restricting the search to molecules
containing a thiol was done to increase the number of active
molecules, as sulfur is known to act as a good ligand for zinc.
To carry out the virtual screening, molecules were conformation-
ally enumerated and docked using the defaults in Omega (v2.4.6.
OpenEye Scientific Software; http://eyesopen.com) and Fred
(v2.2.5 OpenEye Scientific Software; http://eyesopen.com), res-
pectively (Hawkins et al., 2010; Hawkins and Nicholls, 2012;
McGann, 2011). The ten highest scoring virtual candidates with
a thiol within 5 A˚ from the catalytic zinc were selected for
in vitro evaluation (Table S1).
The peptides found by Cathcart et al. (2011) were used to
construct a model for potency with the Autocorrelator. This
model was generated after the Autocorrelator used all available
crystal structures of LasB, Omega (v2.4.6), and Fred (v2.2.5)
to generate conformations. The Autocorrelator-derived model
was then used as the basis for scaffold expansion experiments
(see Supplemental Information) (Lardy et al., 2012).
This sub-library was screened using an in vitro LasB inhibition
assay based on a LasB-cleavable fluorescence resonance en-
ergy transfer peptide substrate (see Supplemental Information)
(Nishino and Powers, 1980). Of these compounds, three showed
dose-dependent inhibition of LasB with half maximal inhibitory
concentration (IC50) values ranging from 15 to 160 mM (Figure 1).
Interestingly, all active compounds (1, 2, and 3) contained an
aromatic core with a mercaptoacetamide side chain, which sug-
gests that this moiety plays an important role as a Zn2+ metal-
binding chelator. We hypothesized that the thiol group and
the electron-rich oxygen are critical for chelating the zinc atom
of LasB, whereas the hydrophobic aromatic core fits in the
ligand-binding cavity of the receptor pocket (Figure 2). Encour-
aged by our initial screening, a small series of compounds based
on the activemercaptoacetamide motif were synthesized. These
compounds contain a diverse array of substituents on the aro-
matic ring, including alkyl, halogens, ethers, and benzylamines.
In addition, we varied the methylene chain length between the484 Chemistry & Biology 22, 483–491, April 23, 2015 ª2015 Elsevieramide and thiol. The results from the LasB inhibition assay are
summarized in Tables S2–S6.
Synthesis of Mercaptoacetamide Prodrugs
Following initial screening of our newly synthesized mercaptoa-
cetamides, we successfully identified ten hits that demonstrated
LasB antagonism (Table 1). Compounds 11, 12, and 13were the
most active with IC50 values ranging from 1.78 mM to 5.94 mM.
We were excited by the potent in vitro activity of the hits identi-
fied, but it is well known that the thiol functionality is prone to
oxidation in vivo. We sought to improve the stability of the com-
pounds using a prodrug approach via acetylation of the thiol. As
shown in SchemeS1, the commercially available aromatic amine
was treated with chloroacetyl chloride to afford the a-chloro
amide intermediate, which was then treated with potassium thi-
oacetate to yield thioesters 11a, 12a, and 13a. These prodrugs
were subsequently hydrolyzed with potassium carbonate before
performing the in vitro LasB inhibition assay.
Modulation of LasB Function in a C. elegans Infection
Model
Having established several potent compounds that modulate
LasB activity in vitro, we sought a simple animal model to provide
us with a foundation for further development of these com-
pounds in vivo. C. elegans has been increasingly used and stud-
ied for its potential as an intermediate model system for drug
discovery between in vitro testing and a mammalian model
(O’Reilly et al., 2014; Ewbank and Zugasti, 2011; Squiban and
Kurz, 2011). C. elegans can succumb to human disease by sim-
ply feeding the worm with the respective pathogen, in converse
worm infectivity can then be ‘‘cured’’ with common antibiotics at
concentrations typically used to treat humans. Moreover, the
C. elegans infection model has many practical advantages,
such as being amenable to low-cost, large-scale in vivo
screening and it does not raise any of the ethical concerns for
drug testing at the early stages of development (Mahajan-MiklosLtd All rights reserved
Table 1. Lead Mercaptoacetamides Identified In Vitro
Compound Structure IC50 (mM)
4 6.98 ± 0.07
5 5.99 ± 0.11
6 7.61 ± 0.03
7 8.19 ± 0.22
8 9.90 ± 0.09
9 7.33 ± 0.02
10 6.90 ± 0.01
11 3.56 ± 0.04
12 1.78 ± 0.01
13 5.94 ± 0.02
Chemistry & Biology 22,et al., 1999; Tan et al., 1999a, 1999b; Kurz and Ewbank, 2000;
Tan and Ausubel, 2000).
We first determined the effect of LasB on the ability of
P. aeruginosa PAO1 to kill C. elegans, our reasoning here being
that C. elegans has been used to compare the global variations
of virulence in a P. aeruginosa ‘‘slow-killing’’ assay. In a typical
C. elegans slow-killing assay, bacterial strains to be tested are
used as a lawn on slow-killing agar plates, substituting in place
of the normal feeding bacterium, Escherichia coli OP50. By sim-
ply ingesting pathogenic bacteria, worms can become infected,
primarily in the intestine although exceptions have been
observed (Dorer and Isberg, 2006). A comparison of median le-
thal time (LT50) values in our present study confirmed that
LasB activity significantly increased P. aeruginosa-induced viru-
lence in a toxic infection compared with a genetic knockout (r <
0.001, Figure 3A). Our data indicate that when C. elegans is fed
with wild-type PAO1, theworms survive up to 9 dayswith an LT50
of 3.9 ± 0.2 days, whereas the lasB-knockout-exposed animals
survive up to 11 days with an LT50 of 6.5 ± 0.5 days. The
extended lifespan observed in animals exposed to the lasB
knockout provides strong evidence that using the C. elegans
slow-killing assay is a valid model to evaluate LasB function in
P. aeruginosa infections. Moreover, the assay can be used to
quickly test and characterize the efficacy of in vitro LasB inhibi-
tors in a whole-animal infection model.
With the C. elegans LasB assay at our beckoning, we next
sought the importance of the inhibitors discovered in our
in vitro assay. The most potent compounds (11, 12, and 13)
and their corresponding thioester prodrugs (11a, 12a, and 13a,
Table 2) were individually supplemented in slow-killing agar
plates at 50 mM. Some of the administered compounds were
able to modestly extend worm half-life, but none were as effec-
tive as 13a. Mercaptoacetamide 13 demonstrated attenuation of
P. aeruginosa virulence only at the early stages of infection with
an LT50 of 4.3 ± 0.1 days. However, when 13 was masked as the
thioacetate, 13a, the half-life of the nematode was extended to
6.2 ± 0.1 days (Figure 3A). As observed in the supplemental bac-
terial cell viability minimum inhibitory concentration assay and
mammalian cell cytotoxicity assay, 13 and 13a had no effect
on bacterial survival ormammalian cell viability at concentrations
up to 50 mM, the highest concentration administered in the
C. elegans slow-killing assay.
Accordingly, we further demonstrated that 13a inhibited
P. aeruginosa infection in C. elegans in a dose-dependent
manner. At 25 mM, the LT50 of infected C. elegans was signifi-
cantly increased to 1.5 days longer than that of wild-type
PAO1 (r < 0.001, Figure 3B). However, when C. elegans was
fed with wild-type PAO1 on plates supplemented at lower com-
pound concentrations (5 and 10 mM), the virulence attenuation
effect was diminished (DLT50 = 0.6 days). Thus, 13a provides a
protective effect from the progression of P. aeruginosa infection
in C. elegans through specific inhibition of LasB function.
Metalloenzyme Selectivity
Metalloproteins play an enormous role inmodulating awide array
of functions in vivo, thus many laboratories are actively pursuing
strategies that can modulate this class of proteins (Raeside and
Strickland, 2012). At a clinical level, a contemporary goal of
any successful therapeutic candidate is that it must possess483–491, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 485
Figure 3. LasB Deletion and Treatment with
13a Extends C. elegans LT50 in a Dose-
Dependent Manner
Survival rate of P. aeruginosa-infected C. elegans
improves upon lasB deletion and supplementation
of 13a in the slow-killing assay.
(A) 13a extends worm LT50 to 6.2 ± 0.1 days re-
sulting in no significant difference between worm
LT50 (6.5 ± 0.5 days) when fed lasB knockout
P. aeruginosa (rR 0.05).
(B) Dose-dependent effect of 13a on survival of
P. aeruginosa-infected C. elegans over time in the
slow-killing assay. lasB knockout (LT50 = 8.3 ±
0.1 days), 25 mM (LT50 = 7.8 ± 0.1 days), 10 mM
(LT50 = 7.0 ± 0.1 days), 5 mM (LT50 = 7.0 ± 0.1 days), 1 mM (LT50 = 6.4 ± 0.1 days), 0.5 mM (LT50 = 5.9 ± 0.1 days), wild-type PAO1 (LT50 = 6.3 ± 0.2 days).
LT50 data were analyzed by ANOVA followed by Tukey’s multiple comparison method to determine significance. Error bars represent SEM values (n = 3). WT,
wild-type.selectivity for the target of interest. Accordingly successful
targeting of a singular metalloprotein appears chemically chal-
lenging, as it is estimated that approximately one third of all pro-
teins aremetalloproteins (Holm et al., 1996).Mercaptoacetamide
13 contains a metal-binding group that could incite promiscuity
with other metalloproteases. To test this notion we screened 13
at 50, 25, and 12.5 mM against two ubiquitous metalloenzymes:
matrix metalloproteinase 2 (MMP-2) and a Zn2+-dependent
histone deacetylase (HDAC, encompassing class I and IIb).
MMP-2 is a Zn2+-dependent endopeptidase that is capable of
breaking down connective tissue including native and denatured
collagens and elastin. Class I and IIb HDACs are known to regu-
late cellular processes via hydrolysis of the acetyl functionality
embedded within protein matrices containing acetyl lysines.
LasB and MMP-2 possess similar characteristics but HDAC
operates under a different mechanism, thus inhibitor selectivity
against these two enzymes would provide a measure of selec-
tivity assurance. As shown in Figure 4, 13 did not inhibit enzyme
activity of HDAC or MMP-2 at a dose range up to 50 mM.
Bioaccumulation and Metabolism of LasB Inhibitors in
C. elegans
As an additional metric of the future potential of these mercap-
toacetamides, we investigated their adsorption and metabolism
in C. elegans. Accordingly, mercaptoacetamides 11, 12, and 13
and their respective prodrugs were examined as a means to
correlate compound bioaccumulation with their bioactivity as
seen in the slow-killing assays. Previous literature has docu-
mented howC. elegans could be resistant to a variety of pharma-
cological perturbations, so that the bioavailability of drug and
drug metabolites in the worm is highly dependent on the drug’s
chemical structure and the drug delivery method (Zheng et al.,
2013; Burns et al., 2010). Therefore, we used the same killing
assay set up for the bioaccumulation test and collected the
worms infected with P. aeruginosa 24 hr after seeding on the
slow-killing assay plate supplemented with individual com-
pounds. Collected worms were washed and homogenized for
liquid chromatography-mass spectrometry (LC-MS) analysis,
and the results are summarized in Table 2. In brief, mercaptoace-
tamides 11 and 11a were not detected in the worm samples
collected, indicating little or no accumulation of these two com-
pounds. Mercaptoacetamides 12 and 12a were also not identi-
fied in the worm homogenates, however, the disulfide form of486 Chemistry & Biology 22, 483–491, April 23, 2015 ª2015 Elsevier12 was observed in both samples. Interestingly, the metabolism
of 13a in C. elegans was more complex compared with 11a and
12a. The first stage of metabolism for 13a was hydrolysis to
generate the active thiol 13, which was further oxidized to form
the corresponding disulfide. Of the three thioacetates, only 13a
readily accumulated in C. elegans and metabolized to the active
thiol form, and in so doing inhibited the function of LasB and
extended the lifespan of C. elegans. It is noteworthy that these
results match the bioactivity assay data as only 13a significantly
attenuated P. aeruginosa virulence in the slow-killing assay,
providing support for our hypothesis that a prodrug strategy
greatly improves the availability of active drug in the host
organism.
Transmission Electron Microscopy
We used transmission electron microscopy (TEM) to visualize
P. aeruginosa colonization, including virulence associated with
LasB and its attenuation from 13a treatment. Orchestrating this
ensemble of events, we could examine the C. elegans intestine
as a means to evaluate pathogenic progression at 48 hr post
infection with/without LasB inhibitor treatment. Bacterial accu-
mulation resulting in penetration of the intestinal lumen was clas-
sified as an unhealthy worm; worms without accumulation (and
intact lumen) were classified as healthy. Using this outline to
judge the infection rate, we scored worms based on frequency
of encounter throughout the respective sample. Visualization of
wild-type PAO1 infection indicated grossly distended intestinal
lumen, widespread shortening of the microvilli, and direct con-
tact of bacterial cells with the microvillar surface (Figure 5A).
In 43% of cross sections (n = 7), we found bacterial cells
that were not in the intestinal lumen (Figure 5B), indicating that
P. aeruginosa cells had penetrated the intestinal wall and
invaded other tissues.
In stark contrast with the P. aeruginosa wild-type, the lasB
knockout exhibited lower levels of host tissue damage in
C. elegans (Figure 5C). Analyzing cross sections, we encoun-
tered less than 20% (n = 10) of intracellular invasion and evaded
bacterial cells in lasB mutant-infected animals compared with
wild-type P. aeruginosa. Most promising was that in C. elegans
treated with 13a, less than 20% (n = 10) of the cross sections
examined had tissue damage, which is comparable with the
lasB mutant-infected worms, suggesting an alleviation in bacte-
rial pathogenesis advancement (Figure 5D). As a control, weLtd All rights reserved
Table 2. Characterization of Structural Metabolites from LasB Inhibitors in C. elegans
Compound Parent Compound Identified Identified Metabolites Identified Metabolites
11
nd nd nd
11a
nd nd nd
12
nd nd
12a
nd nd
13
Yes nd
13a
Yes
nd, none detected.visualized worms fed with E. coli OP50 and observed normal in-
testinal lumina and microvilli structure (Figure S5). Complement-
ing these findings, we also observed that lipid droplets filled
in intestinal epithelial cells characterizing the intestine tissues
from healthy worms (data not shown).
DISCUSSION
Developing a screening platform for antibiotic discovery that will
eventually lead to molecules worthy of translational evaluation
has been a challenge. At the clinical level, one must contend
with the outbreak of resistant bacteria and diminishing returns
from antibiotic research (Lewis, 2013). To address the increasing
challenges in treating antibiotic-resistant bacterial infections, a
range of alternative antibacterial strategies have been proposed.
Of these tactics, investigation of virulence factors has been re-
garded as an emerging second generation antibiotic approach
(Barczak and Hung, 2009; Clatworthy et al., 2007). The wisdom
here is that virulence factors are not essential for cell viability,
hence targeting such factors would impose weak or no selective
pressure for the development and selection of drug resistanceChemistry & Biology 22,(Theuretzbacher, 2009). Arguably, it might be more prudent to
inhibit transcription factors that control a number of virulence
factors, rather than a single target. Taking this stance, LasR is
a transcription factor found in P. aeruginosa and thought to be
a major regulator of a plethora of virulence factors, including
LasB (Kalia, 2013). Yet, strategically targeting LasR also has
drawbacks as, under stress conditions, a signaling pathway
termed IQS can supersede LasR and control a subset of
quorum-controlled genes and thus proteins including LasB
(Lee et al., 2013). Thus, efforts targeting LasR are highly valued;
however, if P. aeruginosa engages the IQS circuitry, then inhibi-
tors of LasR would not disengage LasB. At least for the case of
LasB, wewould argue that singular targeting of a virulence factor
may be more effective.
A viable in vivo assay is especially crucial to overcome the
substantial hurdles in bacterial drug development. Typically,
cultured mammalian cells are used to simulate the potential
host for bacterial infection. Using this approach, antibiotic effi-
ciency and selectivity can be simultaneously determined by
measuring the viability of bacterial and mammalian cells. How-
ever, targeting a virulence factor, in this case LasB, no significant483–491, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 487
Figure 4. Selectivity of Compound 13 for LasB
Compound 13 was shown to be inactive against the metalloenzymes HDAC
and MMP-2.
(A) MMP-2 retains activity in the presence of compound 13 (up to 50 mM).
N-Isobutyl-N-(4-methoxyphenylsufonyl)-glycylhydroxamic acid (NNGH) is a
known MMP-2 inhibitor and was used as a positive control.
(B) HDAC retains activity in the presence of compound 13 (up to 50 mM). Tri-
chostatin A is a knownHDAC inhibitor andwas used as a positive control. Error
bars represent SEM values (n = 3). Data were analyzed by ANOVA followed by
Tukey’s multiple comparison method to determine significance (*significantly
different compared with the positive control, r < 0.0001).bactericidal response is expected. Indeed, none of the mercap-
toacetamides tested displayed toxicity toward P. aeruginosa or
HeLa cells when tested at concentrations upward of 50 mM.
Furthermore, the major host tissue damage caused by LasB
is through the digestion of extracellular matrix proteins, rupturing
cell connections, which renders the suitability of using a
cultured single-cell mixture as an assay model ineffective. A
whole-animal model such as the nematode C. elegans is multi-
cellular with differentiated tissues and distinct organs, thus it is
complex enough to address higher level biological questions
while being simultaneously experimentally tractable. Using this
enabled logic, we recapitulated LasB-induced pathogenesis in
C. elegans, as shown in the nematode intestine TEM cross-sec-
tion data and the extended worm lifespan with lasBmutant bac-
terial infection.
Our laboratory and others have reported several in vitro LasB
inhibitors with micromolar IC50 values and nanomolar competi-488 Chemistry & Biology 22, 483–491, April 23, 2015 ª2015 Elseviertive inhibition constants (Ki) (Cathcart et al., 2011; Garner et al.,
2012; Fullagar et al., 2013). Seeking to improve upon this
research initiative, we used molecular docking to discover a
mercaptoacetamide motif that inhibits the LasB protease. To
improve upon inhibition, a series of molecules were prepared,
which highlight how this scaffolding and its potency could be
improved. Yet, a liability of the mercaptoacetamide motif is
that it is prone to oxidation. Subsequently, we demonstrated
how we could mask the thiol moiety as the thioacetate prodrug,
which is ultimately hydrolyzed by xenobiotic esterases. Having
established that C. elegans is a valuable disease model as
defined by LasB, we examined how our small-molecule inhibi-
tors of LasB would affect P. aeruginosa toxicity in C. elegans.
Excitingly, 13 in its prodrug form was shown to be a highly effi-
cient inhibitor of LasB function at the infection site, exhibiting
the same level of virulence attenuation as the lasBmutant. More-
over, 13 presented a selectivity measure as shown by the lack of
inhibitory activity observed against HDAC and MMP-2.
As ameans to correlate our in vitro and in vivo data, we studied
the metabolism and bioaccumulation of selected LasB inhibi-
tors. Worm lysate was extracted, separated, and visualized by
LC-MS to analyze compound accumulation and metabolism in
the worm, partially mimicking ADME (absorption, distribution,
metabolism, and excretion) studies in animal models. Mercap-
toacetamide 13, as anticipated, was oxidized thus abrogating
in vivo efficacy. However, when 13 was masked in the form of
a prodrug, 13a, we observed the release of the active compound
in the host organism and thus extended worm LT50. When
masked as prodrugs the other mercaptoacetamides, 11 and
12 showed minimal effect on alleviating bacterial virulence and
were either not detected or observed only in the inactive disulfide
form. Presumably, these mercaptoacetamides have different
molecular interactions with the esterases inC. elegans, which re-
sults in different metabolism profiles of these three compounds.
In total, the highly correlated data between IC50, LT50, TEM, and
bioaccumulation substantiate the pertinence of a worm-based
in vivo model system.
In summary, through a virtual screening effort we discovered a
core unit (the mercaptoacetamides) that could inhibit the metal-
loprotease LasB at a non-toxic concentration. Focusing upon
this architecture, a series of molecules were prepared, three of
which potently disabled the protease. The mercaptoacetamides
discovered, while excellent in vitro inhibitors, possessed a
serious liability, a thiol capable of being oxidized. We were
thus led to askwhether a prodrug approachmight serve as a bet-
ter in vivo surrogate. Using a prodrug approach to mask the
reactive thiol, we were successful in translating an initial in vitro
lead into a more drug-like molecule with in vivo efficacy. We
have established how C. elegans can be used to understand
the impact of a bacterial virulence factor and how host-pathogen
interactions betweenC. elegans and P. aeruginosa readily model
the disease state seen in mammalian models. Importantly, this
C. elegans animal infection model has allowed us to systemati-
cally investigate the bioaccumulation of metabolites from an
active compound, thus showing that this model can be used to
study how compounds are metabolized in vivo. It is interesting
to note that compounds that did not translate into in vivo efficacy
did not accumulate in the nematode. From amedicinal chemistry
prospective, this study opens new avenues for the rapidLtd All rights reserved
Figure 5. C. elegans Intestine Cross Sec-
tions as Viewed by Transmission Electron
Microscopy
Cross sections of bacterial accumulation in
C. elegans intestine used for invasion frequency
experiments.
(A) Worms fed with PAO1 demonstrate bacterial
cell accumulation in the lumen and shortened
microvilli due to bacterial penetration.
(B) Worms fed with PAO1 have punctured intestinal
walls.
(C) Worms fed with lasB knockout have normal in-
testinal structure.
(D) Image of PAO1-fed worm treated with 13a,
showing intact intestinal lumen and reversal of
bacterial pathogenesis. Arrows indicate the object
of relevance. Scale bar represents 1 mm.development of novel anti-infective strategies that target specific
virulence mechanisms.
SIGNIFICANCE
Utilizing a lasB genetic knockout, the relevance of this viru-
lence factor in a P. aeruginosa infection model of the nema-
todeC.eleganswasvalidated.Molecular dockingstudies led
to the discovery of the mercaptoacetamide class of non-
peptidic small-molecule inhibitors of LasB. We were able to
show that C. elegans is an excellent translational tool for
the medicinal chemist seeking to develop anti-virulence
compounds, as an in vitro leadwas shown to have in vivo ac-
tivity. Also marshaled through this research was that com-
pound bioaccumulation andmetabolism could be readily as-
sessed in a user-friendly animalmodel. Indeed, this infection
model enables the screening of anti-virulence compounds at
minimal cost comparedwith its expensivemammalian coun-
terparts. Lastly,wewere able to visualize the immediate anti-
virulence restorative effect of a LasB inhibitor using electron
microscopy, as the phenotype mirrored that of the lasB
knockout strain. Importantly, our studies provide not only
tools to expand our understanding of the relevance of bacte-
rial metalloproteases inP. aeruginosa pathogenesis but also
the first steps toward a contemporary goal of validating pro-
teolytic virulence factors, includingLasB, asnew therapeutic
targets for the development of effective treatments for bac-
terial infections.
EXPERIMENTAL PROCEDURES
In Vitro Fluorescence Assay for LasB Activity
LasB was purchased from Elastin Products Company and used as received.
The LasB pro-fluorescent substrate, Abz-Ala-Gly-Leu-Ala-p-nitro-benzyl-
amide (SAG-3905-PI), was purchased from Peptides International and used
as received. An in vitro fluorescence-based peptide cleavage assay wasChemistry & Biology 22, 483–491, April 23, 2015adapted from a previously reported assay and per-
formed in 96-well microtiter plates (Corning Costar,
black with clear bottom). Assays were performed in
100 ml of assay buffer (50 mM Tris-HCl, 2.5 mM
CaCl2, 1% dimethylformamide [pH 7]) containing
2 mg/ml LasB, 250 mM Abz-Ala-Gly-Leu-Ala-p-
nitro-benzyl-amide substrate, and varying concen-tration of inhibitors. The reaction system was pre-incubated at 37C for 30 min
before the addition of peptide substrates and monitored by measuring the in-
crease in fluorescence for 30 min (lex = 340 nm, lem = 415 nm) at 37
C on a
SpectraMax M2e microplate reader (Molecular Devices). LasB activity was
evaluated by the slope during the linear phase of the cleavage as units of fluo-
rescence per unit time. The activities obtained at different compound concen-
trations were analyzed by GraphPad Prism 5 to afford the IC50 values for each
inhibitor identified.
In Vitro Fluorescence Assay for HDAC and MMP-2 Activity
AFluorogenicHDACAssayKit (Green)waspurchased fromBPSBioscienceand
used according to the manufacturer’s instructions. The MMP-2 Fluorometric
DrugDiscovery Kitwas purchased fromEnzo Life Sciences andused according
to themanufacturer’s instructions, with a slight modification as described previ-
ously (Day and Cohen, 2013). Following inhibitor and enzyme incubation (37C
for 30 min), the substrate was added to initiate the reaction. The change in fluo-
rescence (lex = 305 nm, lem = 405 nm) was monitored for 30 min on a Spectra-
Max M2e microplate reader (Molecular Devices). Control wells containing
enzyme and substrate (no inhibitor) were designated as negative controls wells.
The increase in fluorescence in the inhibitor wells was compared with that in the
negative control wells and is presented as a percentage. The negative control
wells were set to 100% enzyme activity and inhibitor wells were normalized
against this value. All assays were performed in triplicate.
C. elegans Slow-Killing Assays
C. elegans slow-killing assays were performed following a previous protocol
with minor modifications. The wild-type C. elegans (Bristol) N2 hermaphrodite
strain was used in the slow-killing assays. Worms were synchronized by hypo-
chlorite treatment of gravid adults. Synchronized worms were grown to L4 or
young adult stage by incubating them at 25C in Nematode Growth Medium
(NGM) as stock for the killing assays. 3.5-cm slow-killing agar plates were
made following the published recipe with the addition of 0.3% DMSO or the
designated testing compounds at 50 mM. One-day-old agar plates were inoc-
ulated with 10 ml of an overnight culture in lysogeny broth medium of
P. aeruginosa PAO1 or lasB knockout (lasB) or E. coli OP50 and incubated
at 37C for 24 hr and at 25C for another 24–48 hr to form a lawn of bacteria.
Nematodes were washed off the stock plates and suspended in a minimal vol-
ume of M9 buffer (pH 6.5). 20–30 L4 stage or adult hermaphrodite worms were
placed on each slow-killing plate for evaluation of bacterial infection. Plates
were incubated at 25C and scored for live worms every 24 hr. A worm was
considered dead when it no longer responded to touch when picked up by aª2015 Elsevier Ltd All rights reserved 489
sterile platinum wire loop. Killing curves represent the mean of three separate
replicate plates per condition.
C. elegans Bioaccumulation Assays
Sample preparation and analysis of worm homogenates were carried out as
reported previously (Gooyit et al., 2014). Mass spectrometry acquisition was
performed in negative electrospray ionization mode with the following param-
eters: capillary voltage = 3.5 kV, nebulizer pressure = 20 psig, drying gas flow =
7 l/min, and gas temperature = 350C. Worm homogenate samples were
analyzed on a Zorbax SB-C18 column (3.5 mm, 1 3 150 mm; Agilent Technol-
ogies). The mobile phase consisted of elution at 0.10 ml/min starting with 70%
A/30% B for 1 min, followed by a 5-min linear gradient to 100% B, and then
100% B for 12 min. The mass filters used for extracting ion chromatograms
were as follows: m/z = 333.910–333.950 for 13a, m/z = 291.900–291.940 for
13, m/z = 584.780–584.850 for the disulfide of 13, m/z = 299.700–300.100
for 11a, m/z = 257.900–258.100 for 11, m/z = 516.700–517.100 for the
disulfide form of 11, m/z = 367.600–368.200 for 12a, m/z = 325.600–326.100
for 12,m/z = 650.400–651.000 for the disulfide form 12. Identification of com-
pounds in theworm homogenateswas confirmed by comparison of high-pres-
sure liquid chromatography retention time and mass spectrum with those of
authentic synthetic standards (Figure S4).
Electron Microscopy
C. elegans infection sample preparation for electron microscopy was the same
as described for the slow-killing assay. After 48 hr incubation at 25C, animals
were collected and incubated in fixation buffer (2.5% glutaraldehyde, 1.0%
paraformaldehyde in 0.05 M sodium cacodylate buffer (pH 7.4) plus 3.0% su-
crose). During the initiation of fixation, animals were cut in half with a surgical
blade in a drop of fixative under a dissecting microscope, fixed overnight at
4C, rinsed in 0.1 M cacodylate buffer, post-fixed in 1.0% osmium tetroxide
0.1 M cacodylate buffer, rinsed in buffer and water, and stained en bloc in 2%
aqueous uranyl acetate. After rinsing in water, animals were embedded in 2%
agarose in PBS, dehydrated through a graded series of ethanol washes to
100%, then 100%propylene oxide, and finally 1:1 propylene oxide/EPON over-
night. Blockswere infiltrated in 100%EPON and then embedded in fresh EPON
overnight at 60C. Thin sections were cut on a Reichert Ultracut E ultramicro-
tome and collected on formvar-coated gold grids. Sections were post-stained
with uranyl acetate and lead citrate and viewed using a JEOL 1011 transmission
electronmicroscopeat 80kVwithanAMTdigital imaging system (AdvancedMi-
croscopy Techniques). For each observation, whenever possible at least ten
cross sections were evaluated and representative images were chosen.
Computational Methodology
Three different structures of LasB (PDB codes 3DBK, 1EZM, 1U4G) were used
in Autocorrelator runs to construct computational models of potency against
LasB (Lardy et al., 2012). While all three structures are reasonably similar,
with subtle differences between them in the catalytic cleft, there was a prefer-
ence by the Autocorrelator for the 3DBK structure. The correlation coefficients
(R2) for the strongest models built with 3DBK, 1EZM, and 1U4G were 0.61,
0.49, and 0.47, respectively.
The model found with the 3DBK structure of LasB employed Omega 2.4.6
(using a maximum of 280 conformations per molecule and a 10-kcal energy
window cutoff) and Fred 2.2.5 (with the chemscore scoring function, shape-
gauss optimization, no MMFF (Merck molecular force fields) refinement,
16.0 A˚ added to the bounding box containing the co-crystalized inhibitor, a
clash_scale of 0.8, a low contour quality, rotational and translational step
size of 1.2, and chemgauss 2 for exhaustive scoring) (Hawkins et al., 2010;
Hawkins and Nicholls, 2012; McGann, 2011). The Autocorrelator turns off all
the pose_select options in Fred by default. The scoring function produced
from the LARS methodology in R contains terms for the metal interaction, hy-
drophobic interactions, and rotatable bonds (McGann et al., 2003; Efron et al.,
2004). The scoring function is shown in Equation 1:
predIC50 = 2:84+Chemscore:RB3 0:36+Chemscore:LIPO
3  0:115+Chemscore:METAL3 0:0785; (Equation 1)
A total of 39,816 thiol-containing purchasable molecules were virtually
screened by this method and were ranked using Equation 1.490 Chemistry & Biology 22, 483–491, April 23, 2015 ª2015 ElsevierSUPPLEMENTAL INFORMATION
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